Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) provide clinical benefits in obesity-related HFpEF, including symptom improvement and potential reverse cardiac remodeling, independent of or in addition to weight loss.
If you have obesity and heart failure with preserved ejection fraction, ask your doctor about SGLT2 inhibitors (like dapagliflozin) or GLP-1 agonists (like semaglutide). These drugs not only help with weight but also directly protect the heart by reducing inflammation and stiffness, improving symptoms and outcomes.
GoodSupportsHIGH confidence
Recent evidence suggests that GLP-1 receptor agonists... as well as MBS may exert cardioprotective effects that extend beyond weight loss. These interventions have been shown to reduce systemic inflammation, improve endothelial function, and attenuate myocardial fibrosis...
Why this rating
Cites major trials (DELIVER, STEP 1 extension, SUMMIT) and observational data.
Source
Time to screen: rationale and roadmap for HFpEF screening in individuals with obesity
Anouk Achten et al. · Heart Failure Reviews · 2025
DOI 10.1007/s10741-025-10540-z
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Standard diagnostic thresholds for natriuretic peptides (BNP/NT-proBNP) are less sensitive in individuals with obesity, potentially missing cases of HFpEF, necessitating adjusted cutoffs or alternative screening scores.Good
- Systematic screening for heart failure with preserved ejection fraction (HFpEF) in asymptomatic or mildly symptomatic individuals with obesity is clinically indicated to enable early detection and intervention, as obesity-related HFpEF presents with distinct pathophysiology and earlier onset.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →